Infectious Diseases Fellowship at Indiana University

@iuidfellowship.bsky.social

#idboardreview #idfellows #idfellowship #IDsky #HIVsky #idmeded

🆕💥Exciting news U.S. FDA Grants Priority Review of New Drug Application for Gilead’s once-daily single-tablet combination(Bictegravir Plus Lenacapavir) regimen for the treatment of HIV in adults who are virologically suppressed PDUFA: August 27, 2026 #idsky www.gilead.com/news/news-de...

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once Daily HIV Treatment of Bictegravir Plus Lenacapavir

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once Daily HIV Treatment of Bictegravir Plus Lenacapavir

gilead.com